LAB5067
Collect
Serum separator tube.
Patient Preparation
Collect specimens before infliximab treatment.
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Unacceptable Conditions
Contaminated, hemolyzed, icteric, or lipemic specimens.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 48 hours; Refrigerated: 4 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Notes
This test is performed pursuant to an agreement with Biomonitor.
Laboratories.Performed
Mon, Wed, Thu, Sat
Methodology
Cell Culture/Quantitative Chemiluminescent Immunoassay/ Semi-Quantitative Chemiluminescent Immunoassay
Reported
2-3 days
Synonyms
- HACA/Infliximab Activity
- LAB5067
- INFLI/HACA
Additional Technical Information
Ordering Recommendations
Evaluate response failure to infliximab therapy. Determine and adjust dosage or identify the need for change to another anti-TNF-α inhibitor.
Reference Interval
| Available Separately | Components | Reference Interval |
|---|---|---|
| No | Infliximab Activity | Not Detected |
| No | Infliximab Neutralizing Antibody Titer | Not Detected |
Interpretive Data
This test measures the capacity of infliximab to neutralize TNF- activity. Additionally, infliximab neutralizing antibodies (NAb) are titered (reporting the highest dilution of patient sera in which NAb activity is detected).
This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.
Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.
This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.
Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.
| IF Infliximab Activity is.... | AND Infliximab Neutralizing Ab. Titer is.... | THEN.... |
|---|---|---|
| Not Detected | Not Detected | A higher dosage of infliximab or shortening the dosing interval may be appropriate. |
| Not Detected | 1:20 or greater | A change to another anti-TNF-α drug may be appropriate. |
| 0.65 ug/mL or greater | Not Detected | A change to another type of therapy (not targeting TNF-α) may be appropriate. |
| 0.65 ug/mL or greater | 1:20 or greater | Repeat testing is suggested to rule out decreasing infliximab activity and/or increasing infliximab neutralizing antibodies. |
CPT Codes
86352x2
| Collection |
LAB5067
Collect
Serum separator tube.
Patient Preparation
Collect specimens before infliximab treatment.
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Unacceptable Conditions
Contaminated, hemolyzed, icteric, or lipemic specimens.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 48 hours; Refrigerated: 4 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Notes
This test is performed pursuant to an agreement with Biomonitor.
| Ordering |
Performed
Mon, Wed, Thu, Sat
Methodology
Cell Culture/Quantitative Chemiluminescent Immunoassay/ Semi-Quantitative Chemiluminescent Immunoassay
Reported
2-3 days
Synonyms
- HACA/Infliximab Activity
- LAB5067
- INFLI/HACA
Additional Technical Information
Ordering Recommendations
Evaluate response failure to infliximab therapy. Determine and adjust dosage or identify the need for change to another anti-TNF-α inhibitor.
| Result Interpretation |
Reference Interval
| Available Separately | Components | Reference Interval |
|---|---|---|
| No | Infliximab Activity | Not Detected |
| No | Infliximab Neutralizing Antibody Titer | Not Detected |
Interpretive Data
This test measures the capacity of infliximab to neutralize TNF- activity. Additionally, infliximab neutralizing antibodies (NAb) are titered (reporting the highest dilution of patient sera in which NAb activity is detected).
This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.
Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.
This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.
Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.
| IF Infliximab Activity is.... | AND Infliximab Neutralizing Ab. Titer is.... | THEN.... |
|---|---|---|
| Not Detected | Not Detected | A higher dosage of infliximab or shortening the dosing interval may be appropriate. |
| Not Detected | 1:20 or greater | A change to another anti-TNF-α drug may be appropriate. |
| 0.65 ug/mL or greater | Not Detected | A change to another type of therapy (not targeting TNF-α) may be appropriate. |
| 0.65 ug/mL or greater | 1:20 or greater | Repeat testing is suggested to rule out decreasing infliximab activity and/or increasing infliximab neutralizing antibodies. |
| Administrative |
CPT Codes
86352x2